8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549



                                    FORM 8-K
                                 CURRENT REPORT



     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



        Date of Report (Date of earliest event reported) October 14, 2004



                         Progenics Pharmaceuticals, Inc.
              -----------------------------------------------------
             (Exact name of registrant as specified in its charter)



         Delaware                   000-23143                13-3379479
- ----------------------------    -----------------   ---------------------------
(State or other jurisdiction       (Commission             (IRS Employer
     of incorporation)             File Number)          Identification No.)



        777 Old Saw Mill River Road, Tarrytown, New York      10591
    ------------------------------------------------------------------------
           (Address of principal executive offices)         (Zip Code)


        Registrant's telephone number, including area code (914) 789-2800
                                                          -----------------


        ----------------------------------------------------------------
         (Former name or former address, if changed since last report.)






Section 8 - Other Events

         Item 8.01       Other Events

                         Progenics announced the appointment of Alton B. Kremer,
                         M.D., Ph.D. to Vice President, Clinical Research, a
                         newly created position in the Company. Dr. Kremer will
                         be responsible for medical aspects of the Company's
                         clinical trials.


Section 9 - Financial Statements and Exhibits

         Item 9.01       Financial Statement and Exhibits

                (c)      the following exhibits are filed with this report

                          Exhibit Number               Description
                          99.1              Press release dated October 14, 2004
                                                                ----------------











                                   SIGNATURES

                  Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                                   PROGENICS PHARMACEUTICALS, INC.


                                   By:  /s/ ROBERT A. MCKINNEY
                                     -------------------------------------------
                                            Robert A. McKinney
                                            Vice President, Finance & Operations


Date: October 14, 2004

EX-99.1

                                                                   EXHIBIT 99.1

Progenics Expands Senior Management Team; Dr. Alton B. Kremer Named
Vice President of Clinical Research

    TARRYTOWN, N.Y.--(BUSINESS WIRE)--Oct. 14, 2004--Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the appointment
of Alton B. Kremer, M.D., Ph.D. to Vice President, Clinical Research,
a newly created position in the Company. In his new capacity, Dr.
Kremer will be responsible for medical aspects of the Company's
clinical trials. In particular, he will lead the studies of
methylnaltrexone, an investigational drug designed to reverse the
debilitating side effects of opioid pain medication and to treat
post-operative ileus.
    Dr. Kremer joins Progenics from Purdue Pharma, where he was
Executive Medical Director and directed opioid clinical research
programs. Previously, Dr. Kremer was at Janssen Pharmaceutica of the
Johnson & Johnson Family of Companies, where he held several
positions, the most recent of which was Senior Director, Clinical
Research. He earned his M.D. and Ph.D. in Biochemistry at Case Western
Reserve University and holds a B.A. degree in Biology and Chemistry
from Wesleyan University.
    "We are extremely pleased that Dr. Kremer has joined Progenics'
medical team," said Paul J. Maddon, M.D., Ph.D., Progenics Chairman
and CEO. "His 18 years of clinical research experience in developing
drugs primarily for pain and palliative care, AIDS and cancer, are an
excellent match for our development programs in these same therapeutic
areas. I look forward to working with Dr. Kremer in expanding our
clinical research activities."

    Company Profile

    Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a
biopharmaceutical company focusing on the development and
commercialization of innovative therapeutic products to treat the
unmet medical needs of patients with debilitating conditions and
life-threatening diseases. The Company has five product candidates in
clinical development and several others in preclinical development. In
symptom management and supportive care, the Company is developing
methylnaltrexone (MNTX) to treat the debilitating side effects of
opioid-based pain relievers without interfering with pain relief. MNTX
is in pivotal phase 3 clinical testing for treatment of opioid-induced
constipation in patients with advanced medical illness and may be the
Company's first product candidate to be approved for marketing. MNTX
is also being studied for the treatment of post-operative ileus and
relief of opioid-induced constipation in patients with chronic pain.
In the area of HIV infection, the Company is developing viral-entry
inhibitors, including PRO 542, a genetically engineered molecule
designed to selectively target and neutralize HIV (in phase 2
studies), and PRO 140, a monoclonal antibody designed to target the
HIV coreceptor CCR5 (in phase 1 studies). In addition, the Company is
conducting research on ProVax, a novel prophylactic HIV vaccine. The
Company, in collaboration with Cytogen Corporation, is developing
immunotherapies for prostate cancer, including monoclonal antibodies
directed against prostate-specific membrane antigen (PSMA), a protein
found on the surface of prostate cancer cells. The Company is also
developing vaccines designed to stimulate an immune response to PSMA.
A recombinant PSMA vaccine is in phase 1 clinical testing. The Company
is also studying a cancer vaccine, GMK, in phase 3 clinical trials for
the treatment of malignant melanoma.

    DISCLOSURE NOTICE: The information contained in this document is
current as of October 14, 2004. This press release contains
forward-looking statements. Any statements contained herein that are
not statements of historical fact may be forward-looking statements.
When the Company uses the words 'anticipates,' 'plans,' 'expects' and
similar expressions, it is identifying forward-looking statements.
Such forward-looking statements involve risks and uncertainties which
may cause the Company's actual results, performance or achievements to
be materially different from those expressed or implied by
forward-looking statements. Such factors include, among others, the
uncertainties associated with product development, the risk that
clinical trials will not commence or proceed as planned, the risks and
uncertainties associated with dependence upon the actions of our
corporate, academic and other collaborators and of government
regulatory agencies, the risk that our licenses to intellectual
property may be terminated because of our failure to have satisfied
performance milestones, the risk that products that appear promising
in early clinical trials do not demonstrate efficacy in larger-scale
clinical trials, the risk that we may not be able to manufacture
commercial quantities of our products, the uncertainty of future
profitability and other factors set forth more fully in the Company's
Annual Report on Form 10-K for the fiscal year ended December 31, 2003
and other reports filed with the Securities and Exchange Commission,
to which investors are referred for further information. In
particular, the Company cannot assure you that any of its programs
will result in a commercial product.
    Progenics does not have a policy of updating or revising
forward-looking statements and assumes no obligation to update any
forward-looking statements contained in this document as a result of
new information or future events or developments. Thus, it should not
be assumed that the Company's silence over time means that actual
events are bearing out as expressed or implied in such forward-looking
statements.

    Editor's Note:
    Additional information on Progenics is available at
http://www.progenics.com

    CONTACT: Progenics Pharmaceuticals, Inc.
             Richard W. Krawiec, Ph.D., 914-789-2800
             rkrawiec@progenics.com